Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Phase 1 Study of AMG 337, a Highly Selective Small-Molecule MET Inhibitor, in Patients With Advanced Solid Tumors.

Hong DS, LoRusso PM, Hamid O, Janku F, Kittaneh M, Catenacci DVT, Chan E, Bekaii-Saab T, Gadgeel S, Loberg RD, Amore BM, Hwang YC, Tang R, Ngarmchamnanrith G, Kwak EL.

Clin Cancer Res. 2018 Nov 13. pii: clincanres.1341.2018. doi: 10.1158/1078-0432.CCR-18-1341. [Epub ahead of print]

PMID:
30425090
2.

Moving Precision Oncology Forward Amid Myths and Misconceptions.

Janku F, Hess KR, Yap TA.

JAMA Oncol. 2018 Nov 8. doi: 10.1001/jamaoncol.2018.5064. [Epub ahead of print] No abstract available.

PMID:
30419079
3.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies.

Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F.

Cancer. 2018 Nov 1. doi: 10.1002/cncr.31812. [Epub ahead of print]

PMID:
30383888
4.

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer.

Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S.

Oncotarget. 2018 Sep 7;9(70):33258-33270. doi: 10.18632/oncotarget.25947. eCollection 2018 Sep 7.

5.

BRAF alterations in primary brain tumors.

Maraka S, Janku F.

Discov Med. 2018 Aug;26(141):51-60.

6.

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.

Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS.

Oncotarget. 2018 Sep 4;9(69):33232-33243. doi: 10.18632/oncotarget.26075. eCollection 2018 Sep 4.

7.

A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.

Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM.

Cancer Chemother Pharmacol. 2018 Nov;82(5):877-885. doi: 10.1007/s00280-018-3680-y. Epub 2018 Sep 4.

PMID:
30182147
8.

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL.

Oncologist. 2018 Nov;23(11):1300-1309. doi: 10.1634/theoncologist.2017-0498. Epub 2018 Aug 23.

PMID:
30139837
9.

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.

Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F.

Oncologist. 2018 Aug 14. pii: theoncologist.2018-0058. doi: 10.1634/theoncologist.2018-0058. [Epub ahead of print]

PMID:
30108156
10.

Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.

Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00245. Epub 2018 Apr 25.

11.

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D.

Cancer Chemother Pharmacol. 2018 Sep;82(3):419. doi: 10.1007/s00280-018-3641-5.

PMID:
30014222
12.

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Patnaik A, Gordon M, Tsai F, Papadopoulous K, Rasco D, Beeram SM, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D.

Cancer Chemother Pharmacol. 2018 Sep;82(3):407-418. doi: 10.1007/s00280-018-3623-7. Epub 2018 Jun 20. Erratum in: Cancer Chemother Pharmacol. 2018 Jul 16;:.

13.

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.

Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V.

Lung Cancer. 2018 Jun;120:137-141. doi: 10.1016/j.lungcan.2018.03.020. Epub 2018 Apr 11.

PMID:
29748008
14.

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.

Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D.

Br J Cancer. 2018 May;118(11):1419-1424. doi: 10.1038/s41416-018-0068-z. Epub 2018 Apr 26.

PMID:
29695765
15.

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.

Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V.

Mol Cancer Ther. 2018 Jul;17(7):1595-1601. doi: 10.1158/1535-7163.MCT-17-1107. Epub 2018 Apr 13.

PMID:
29654067
16.

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.

Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia NS, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F.

Ann Oncol. 2018 Jun 1;29(6):1445-1453. doi: 10.1093/annonc/mdy119.

PMID:
29635542
17.

Advances on the BRAF Front in Colorectal Cancer.

Janku F.

Cancer Discov. 2018 Apr;8(4):389-391. doi: 10.1158/2159-8290.CD-18-0125.

PMID:
29610287
18.

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.

Mendzelevski B, Ferber G, Janku F, Li BT, Sullivan RJ, Welsch D, Chi W, Jackson J, Weng O, Sager PT.

Cancer Chemother Pharmacol. 2018 Jun;81(6):1129-1141. doi: 10.1007/s00280-018-3564-1. Epub 2018 Mar 30.

19.

Targeting the PI3K pathway in cancer: are we making headway?

Janku F, Yap TA, Meric-Bernstam F.

Nat Rev Clin Oncol. 2018 May;15(5):273-291. doi: 10.1038/nrclinonc.2018.28. Epub 2018 Mar 6. Review.

PMID:
29508857
20.

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.

Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V.

Br J Cancer. 2018 Mar 20;118(6):763-769. doi: 10.1038/bjc.2017.480. Epub 2018 Feb 20.

PMID:
29462132
21.

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J.

J Clin Oncol. 2018 May 1;36(13):1291-1299. doi: 10.1200/JCO.2017.72.7107. Epub 2018 Feb 5.

22.

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.

Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V.

J Immunother Cancer. 2017 Dec 19;5(1):100. doi: 10.1186/s40425-017-0301-y.

23.

Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.

Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J.

Ann Oncol. 2018 Apr 1;29(4):1076. doi: 10.1093/annonc/mdx776. No abstract available.

PMID:
29253076
24.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

PMID:
29247021
25.

Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients.

Chan OTM, Furuya H, Pagano I, Shimizu Y, Hokutan K, Dyrskjøt L, Jensen JB, Malmstrom PU, Segersten U, Janku F, Rosser CJ.

Oncotarget. 2017 Sep 6;8(59):99707-99721. doi: 10.18632/oncotarget.20686. eCollection 2017 Nov 21.

26.

Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.

Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F.

Mol Cancer Ther. 2018 Mar;17(3):671-676. doi: 10.1158/1535-7163.MCT-17-0673. Epub 2017 Dec 13.

PMID:
29237802
27.

Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors.

Ghosh P, Chandler AG, Hobbs BP, Sun J, Rong J, Hong D, Subbiah V, Janku F, Naing A, Hwu WJ, Ng CS.

J Comput Assist Tomogr. 2018 May/Jun;42(3):357-364. doi: 10.1097/RCT.0000000000000686.

PMID:
29189398
28.

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.

Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V.

Sci Rep. 2017 Nov 21;7(1):15963. doi: 10.1038/s41598-017-13114-8.

29.

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.

Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A.

Invest New Drugs. 2018 Aug;36(4):638-646. doi: 10.1007/s10637-017-0534-0. Epub 2017 Nov 21.

PMID:
29159766
30.

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.

Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA.

Oncotarget. 2017 Aug 3;8(50):87163-87173. doi: 10.18632/oncotarget.19897. eCollection 2017 Oct 20.

31.

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.

Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00002. Epub 2017 Sep 8.

32.

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.

Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F.

Clin Cancer Res. 2018 Jan 1;24(1):181-188. doi: 10.1158/1078-0432.CCR-17-2007. Epub 2017 Oct 19.

PMID:
29051321
33.

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.

Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS.

Invest New Drugs. 2018 Jun;36(3):416-423. doi: 10.1007/s10637-017-0513-5. Epub 2017 Oct 19.

PMID:
29047029
34.

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.

Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F.

Breast Cancer Res. 2017 Aug 15;19(1):93. doi: 10.1186/s13058-017-0878-6.

35.

Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape.

Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DS.

Oncoscience. 2017 Jun 23;4(5-6):47-56. doi: 10.18632/oncoscience.352. eCollection 2017 May.

36.

Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.

Janku F.

Cancer Treat Rev. 2017 Sep;59:93-101. doi: 10.1016/j.ctrv.2017.07.005. Epub 2017 Jul 18. Review.

37.

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.

Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS.

Clin Cancer Res. 2017 Jul 20. doi: 10.1158/1078-0432.CCR-16-3027. [Epub ahead of print]

PMID:
28729355
38.

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.

Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS.

Clin Cancer Res. 2017 Sep 15;23(18):5648-5656. doi: 10.1158/1078-0432.CCR-17-0291. Epub 2017 May 23.

39.

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer.

Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S.

Oncotarget. 2017 May 16;8(20):33796-33806. doi: 10.18632/oncotarget.16840.

40.

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.

Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS.

J Immunother Cancer. 2017 Apr 18;5:35. doi: 10.1186/s40425-017-0238-1. eCollection 2017.

41.

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.

Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V.

Oncotarget. 2017 Jun 13;8(24):39254-39267. doi: 10.18632/oncotarget.16845.

42.

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.

Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS.

JCI Insight. 2017 Apr 20;2(8). pii: 90380. doi: 10.1172/jci.insight.90380. [Epub ahead of print]

43.

Circulating tumor DNA-From bench to bedside.

Lim JSJ, Janku F, Yap TA.

Curr Probl Cancer. 2017 May - Jun;41(3):212-221. doi: 10.1016/j.currproblcancer.2017.02.005. Epub 2017 Mar 1.

PMID:
28416241
44.

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A.

Invest New Drugs. 2017 Oct;35(5):616-626. doi: 10.1007/s10637-017-0442-3. Epub 2017 Feb 13.

45.

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.

Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F.

Clin Cancer Res. 2017 Jul 15;23(14):3657-3666. doi: 10.1158/1078-0432.CCR-16-2592. Epub 2017 Jan 17.

46.

Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.

Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F.

Ann Oncol. 2017 Mar 1;28(3):642-650. doi: 10.1093/annonc/mdw670.

47.

International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant.

Whale AS, Devonshire AS, Karlin-Neumann G, Regan J, Javier L, Cowen S, Fernandez-Gonzalez A, Jones GM, Redshaw N, Beck J, Berger AW, Combaret V, Dahl Kjersgaard N, Davis L, Fina F, Forshew T, Fredslund Andersen R, Galbiati S, González Hernández Á, Haynes CA, Janku F, Lacave R, Lee J, Mistry V, Pender A, Pradines A, Proudhon C, Saal LH, Stieglitz E, Ulrich B, Foy CA, Parkes H, Tzonev S, Huggett JF.

Anal Chem. 2017 Feb 7;89(3):1724-1733. doi: 10.1021/acs.analchem.6b03980. Epub 2017 Jan 18.

PMID:
27935690
48.

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.

Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL.

JAMA Oncol. 2017 Apr 1;3(4):509-515. doi: 10.1001/jamaoncol.2016.5281.

PMID:
27893038
49.

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.

Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S.

Cancer Med. 2016 Dec;5(12):3437-3444. doi: 10.1002/cam4.956. Epub 2016 Nov 23.

50.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.

Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM Jr, Blumenschein G Jr.

J Thorac Oncol. 2017 Mar;12(3):556-566. doi: 10.1016/j.jtho.2016.11.2218. Epub 2016 Nov 19.

Supplemental Content

Support Center